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Structural studies of glycoproteins and their complexes provide critical insights
into their roles in normal physiology and disease. Most glycoproteins contain
N-linked glycosylation, a key post-translation modification that critically affects
protein folding and stability and the binding kinetics underlying protein
interactions. However, N-linked glycosylation is often an impediment to yielding
homogeneous protein preparations for structure determination by X-ray
crystallography or other methods. In particular, obtaining diffraction-quality
crystals of such proteins and their complexes often requires modification of both
the type of glycosylation patterns and their extent. Here, we demonstrate the
benefits of producing target glycoproteins in the GlycoDelete human embryonic
kidney 293 cell line that has been engineered to produce N-glycans as short
glycan stumps comprising N-acetylglucosamine, galactose and sialic acid.
Protein fragments of human Down syndrome cell-adhesion molecule and
colony-stimulating factor 1 receptor were obtained from the GlycoDelete cell
line for crystallization. The ensuing reduction in the extent and complexity of
N-glycosylation in both protein molecules compared with alternative glyco-
engineering approaches enabled their productive deployment in structural
studies by X-ray crystallography. Furthermore, a third successful implementa-
tion of the GlycoDelete technology focusing on murine IL-12B is shown to lead
to N-glycosylation featuring an immature glycan in diffraction-quality crystals. It
is proposed that the GlycoDelete cell line could serve as a valuable go-to option
for the production of homogeneous glycoproteins and their complexes for
structural studies by X-ray crystallography and cryo-electron microscopy.
1. Introduction
N-Glycosylation (NG) is a prominent protein post-translational
modification that involves the covalent linkage of a carbo-
hydrate to an asparagine. NG sites can be predicted on the
basis of the amino-acid sequence surrounding the affected
amino acid, based on the consensus sequence Asn-X-Thr/Ser,
where X is any amino acid except for proline (Apweiler et al.,
1999). N-Glycosylation is encountered in more than 10% of
the mammalian proteome (Zielinska et al., 2010) and is
enriched in proteins following the secretory pathway, such as
cell-surface receptors, cell-adhesion molecules and secreted
glycoproteins (Zielinska et al., 2012). To employ N-glycosyl-
ated proteins in structural studies, it is often imperative to
ensure proper glycosylation during protein expression. Since
bacterial systems do not offer a comparable glycosylation
machinery, several eukaryotic protein-expression systems are
specifically used to ensure proper N-glycosylation. The most
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commonly used expression systems for the production of
recombinant glycoproteins are human embryonic kidney 293
(HEK293), Chinese hamster ovary (CHO), Spodoptera
frugiperda (e.g. Sf9), Trichoplusia ni (e.g. HighFive), Dros-
ophila melanogaster (e.g. S2) and Pichia pastoris cells.
The chemical composition of N-glycans differs among
species and may impact protein folding and expression yield
when heterologous proteins are expressed (Chang et al., 2007).
Assembled from a common pentasaccharide core, mammalian
N-glycosylation is complex and the ensuing glycan trees
display a wide variety of branches of varying sugar composi-
tion. Although mammalian protein-expression systems are
relatively costly, they are preferred for the expression of
secreted mammalian proteins to ensure native-like glycosyl-
ation, which should support protein folding and function.
However, crystallogenesis can be hampered by the extent and
heterogeneity of N-glycans. This is because such post-
translational modification sites are found on the protein
surface and may interfere with potential crystal-packing
interfaces that are necessary to construct a well ordered
crystalline lattice. Larger, branched glycan structures may
introduce conformational flexibility; while they can facilitate
crystallization, the diffraction properties of these crystals are
often poor.
Here, we present the use of the GlycoDelete (GD) HEK
cell line for protein crystallization, which produces homo-
geneous mature-like trisaccharide glycan stubs (Meuris et al.,
2014). The glycan stubs do not need further enzymatic
processing, and we show that for heavily glycosylated
fragments of human colony-stimulating factor 1 receptor
(CSF-1R), murine IL-12B and human Down syndrome cell-
adhesion molecule (DSCAM) the NG modifications facilitate
the production of diffraction-quality crystals. The GD cell line
is derived from the HEK293S MGAT1/ cell line and has
been transformed with Golgi-resident EndoT (an endo--N-
acetylglucosaminidase similar to EndoH). This enzyme
processes the Man5GlcNAc2 glycans, allowing the NG to be
further processed by native Golgi-resident enzymes to
generate mature-like glycans consisting of one GlcNac (which
can be fucosylated), one galactose (Gal) and one sialic acid
(Neu5Ac). We present a detailed analysis of the glycan
structures of the crystallized proteins and show examples
where the use of the GD cell line improves crystal packing and
alters dynamics in glycan maturation. Together, these exam-
ples suggest that the GD cell line can serve as a key option to
obtain homogeneous samples of glycoproteins for structural
studies, in particular for the improvement of the X-ray
diffraction properties of N-glycosylated proteins.
2. Materials and methods
2.1. Cloning and expression of receptor fragments
To facilitate crystallization of the netrin-binding region of
human DSCAMIg7–Ig9, the DSCAM fragment covering resi-
dues 595–884 was codon-optimized and synthesized by
GenScript based on the amino-acid sequence from UniProt ID
O60469. The fragment was inserted into the pXLG vector
(Backliwal et al., 2008) using restriction-site cloning between a
34-residue signal peptide from pregnancy-specific glyco-
protein 1 (UniProt ID P11464) and a 6His C-terminal tag
followed by two stop codons (Finci et al., 2014).
The HEK293 GlycoDelete cell line was obtained at passage
number 10 from a stock kindly provided by Nico Callewaert
(VIB–UGent Center for Medical Biotechnology, Ghent,
Belgium), and cells from this passage number were cultured
for adaptation to adherent conditions. The cells from subse-
quent passage numbers were used for protein expression until
a maximum passage number of 20. For large-scale expression,
both wild-type HEK293T (ATCC CRL-11268) and HEK293
GD cells were seeded into roller bottles. The GD cells are less
adherent, and required a low roller speed incubation period of
4 h following transfer. After 72 h, the cells were transfected
with DNA–polyethylenimine (PEI) complexes. Per roller
bottle (300 ml expression volume), 50 ml transfection mixture
containing 500 mg DNA at a 1:1 DNA:PEI ratio in Dulbecco’s
Modified Eagle’s Medium (DMEM) was used. The GD cells
were maintained at higher serum concentrations (normally
10%; 1% during expression) than wild-type cells (normally
2%; 1–0.1% during expression). The conditioned media were
harvested five days after transfection, filtered (0.27 mm) and
supplemented with 1 mM sodium azide to prevent microbial
growth. Protein yields from a 2.4 l GD culture were typically
0.7 mg l1 after nickel-affinity purification, size-exclusion
chromatography (SEC) and sample concentration, whereas
the wild-type cells yielded 1.25 mg l1. This reduction in
protein yield from the engineered cell line is similar to that
observed for HEK293S MGAT1/ cells.
For murine IL-12B, the reference sequence (NM_
001303244.1) encoding the full-length protein (residues Met1–
Ser335) was synthesized by GeneArt and was a kind gift from
Complix n.v., Ghent, Belgium. The coding sequence was
cloned between the EcoRI and KpnI sites in the pHLsec
vector in frame with a C-terminal hexahistidine tag. Protein
expression was performed in accordance with previously
published protocols (Aricescu et al., 2006). In brief, adherent
GD cells growing in DMEM + 10% fetal calf serum (FCS)
were expanded in T175 cell-culture-treated flasks under
standard sterile cell-culture techniques. Upon reaching 80%
confluency, the medium was exchanged for serum-free DMEM
supplemented with 3.6 mM valproic acid (VPA) and the cells
were transfected utilizing branched 25 kDa PEI as a trans-
fection reagent. A 1:1.5 plasmid:PEI ratio was used. The
conditioned medium was harvested five days post-transfection
and was clarified by centrifugation and filtration prior to
purification. The C-terminal 6His tag enabled capture of the
protein from the conditioned medium by immobilized metal-
affinity chromatography (IMAC) followed by size-exclusion
chromatography (SEC). The size-exclusion chromatogram
clearly revealed both monomeric and dimeric IL-12B. The
dimeric fractions were pooled and finally polished by anion
exchange on Mono Q resin. The loading and elution buffers
for anion exchange were low-salt HBS (20 mM HEPES pH
7.4, 50 mM NaCl) and high-salt HBS (20 mM HEPES pH 7.4,
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500 mM NaCl), respectively. Elution from the Mono Q
column was performed with a linear gradient, in which the
IL-12B homodimer eluted at a conductivity of 16 mS cm1.
The cloning, expression and purification of human CSF-1R
have previously been reported (Felix et al., 2015; Elegheert
et al., 2011). In brief, for CSF-1R comprising extracellular
domains 1–3 (CSF-1RD1–D3), we expressed the glycosylation
mutants N73Q, N153Q, N240Q and N275Q in HEK293T and
HEK293S MGAT1/ cells. All cell lines were grown adher-
ently in 175 cm3 tissue-culture flasks in DMEM supplemented
with 10% FCS and 3.6 mM VPA until they reached 70–80%
confluency. The medium was then exchanged to serum-free
DMEM supplemented with 3.6 mM VPA and the cells were
transfected by adding DNA:PEI complexes in a 1:1.5 ratio.
The conditioned medium was harvested five days post-
transfection, centrifuged for 10 min at 6000g and filtered
through a 0.22 mm filter. Both cell lines produced about 3 mg
of CSF-1RD1–D3 per litre of culture after purification by IMAC
and SEC.
2.2. Crystallization
Purified DSCAMIg7–Ig9 expressed in both HEK293T and
HEK293 GlycoDelete cells was concentrated in 20 mM
HEPES pH 7.4, 100 mM NaCl, 1 mM DTT using a 10 kDa
Amicon Ultra-4 centrifugal unit to 5 and 7.5 mg ml1,
respectively, and subjected to crystallization screening in
100 nl + 100 nl sitting drops using a Mosquito robot (TTP
Labtech). DSCAMIg7–Ig9 obtained from wild-type HEK293T
cells crystallized within seven days at 19C in a rod-like
morphology in 0.05 M magnesium acetate, 10%(w/v) PEG
8000, 0.1 M sodium acetate (condition H9 from The PEGs II
Suite, Qiagen). Despite several crystal-optimization attempts,
the crystals of HEK293T-expressed DSCAMIg7–Ig9 yielded
only poor diffraction (8–13 Å). Cube-shaped crystals of
DSCAMIg7–Ig9 obtained by HEK293 GlycoDelete expression
appeared within 1–3 days in 0.2 M calcium acetate, 10%(w/v)
PEG 8000, 0.1 M HEPES pH 7.5 (condition H8 from The
PEGs II Suite, Qiagen). Further optimization by additive
screening (Additive Screen, Hampton Research) and/or
manual hanging-drop vapor-diffusion experiments containing
a 1.2 ml volume of protein solution and a 1.8 ml volume of
mother liquor yielded single and larger crystals that diffracted
to resolutions in the range 1.85–3 Å. The best diffracting
crystal (1.85 Å resolution) was obtained in 3%(v/v) glycerol,
0.2 M calcium acetate, 10%(w/v) PEG 8000, 0.1 M HEPES pH
7.5. Crystallization conditions are summarized in Table 1.
For IL-12B, the top elution fraction from anion-exchange
chromatography was already found to be highly concentrated
at 7 mg ml1 and was therefore used in crystallization trials.
Extensive commercial sparse-matrix screens were set up with
100 nl protein solution and 100 nl mother liquor in a sitting-
drop geometry with a Mosquito robot at 287 K. Multiple hits
were identified and optimized. An original hit in condition F2
of the Morpheus I screen from Molecular Dimensions
(120 mM monosaccharides, 50 mM imidazole, 50 mM MES
pH 6.5, 20% ethylene glycol, 10% PEG 8000) gave rise to the
best diffracting crystal.
Crystallization of the CSF-1–CSF-1RD1–D3 complex has
previously been reported (Felix et al., 2015). In brief, the top
fractions from the final size-exclusion chromatography of
complexes of glycosylation mutants of CSF-1RD1–D3 produced
in HEK293T, HEK293S MGAT1/ or GD cells were
concentrated to approximately 7.4 mg ml1 and used to set up
multiple commercial sparse-matrix screens. Crystallization
screens were set up by mixing 100 nl protein solution and
100 nl mother liquor in both sitting-drop and hanging-drop
vapor-diffusion geometry using a Mosquito robot (TTP
Labtech). The best diffracting crystals were obtained from
CSF-1RD1–D3 N240Q expressed in HEK293 GD cells in a
condition consisting of 0.2 M lithium sulfate monohydrate,
0.1 M Tris pH 8.5, 28%(w/v) PEG 3350. The crystals were
incubated in stabilizing solution consisting of 35%(w/v) PEG
3350, 5% ethylene glycol prior to flash-cooling.
2.3. Data collection, crystal structure determination and
refinement
Crystals of DSCAMIg7–Ig9 expressed in HEK293 Glyco-
Delete cells were harvested and soaked in a cryoprotectant
solution consisting of 0.2 M calcium acetate, 10%(w/v) PEG
8000, 0.1 M HEPES pH 7.5, 20%(v/v) glycerol prior to flash-
cooling to 100 K. X-ray diffraction data were collected at
EMBL Hamburg on the P13 beamline at the PETRA III
synchrotron, DESY, Hamburg equipped with a PILATUS 6M
detector (25 Hz, 450 mm sensor thickness) and an MD2
diffractometer (Cipriani et al., 2007). The data were processed
using XDS (Kabsch, 2010) and merged and scaled with
AIMLESS (Evans & Murshudov, 2013), yielding a data set to
1.85 Å resolution. The crystal belonged to the monoclinic
space group C2, with unit-cell parameters a = 78.6, b = 71.4,
c = 92.2 Å,  = 113.1. Crystal solvent-content analysis based
on the Matthews coefficient indicated the presence of one
molecule in the asymmetric unit, corresponding to 67%
solvent content. The structure was determined by molecular
replacement with MOLREP (Vagin & Teplyakov, 2010) using
the structure of the Drosophila DSCAM Ig7 domain (PDB
entry 4wvr; Li et al., 2016) as a search model. Two domains,
assigned as Ig7 and Ig9, were found by MOLREP, and the
missing Ig8 domain was built based on structural alignment
with the Ig7–Ig8 fragment from the Drosophila DSCAM Ig1–
Ig8 structure (PDB entry 3dmk; Sawaya et al., 2008) using the
Ig7 domain. The model was refined by ten cycles of rigid-body
refinement followed by iterative cycles of restrained refine-
ment and manual model corrections. TLS refinement was
conducted in the later stages of the refinement. Refinement
steps were performed with REFMAC5 (Murshudov et al.,
2011) with a randomly selected 5% of reflections used for
cross-validation. Manual model building and the addition of
water and N-glycan residues was performed in Coot (Emsley
et al., 2010). The model was refined to an R factor of 0.189 and
an Rfree of 0.217, and its stereochemistry was validated using
the MolProbity web service (Chen et al., 2010), indicating that
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there were no residues in the disallowed regions of the
Ramachandran plot. The final data-collection and refinement
statistics are summarized in Table 2.
For IL-12B, the crystals were cryoprotected in mother
liquor and vitrified in liquid nitrogen. X-ray diffraction data
were collected at EMBL Hamburg on the P14 beamline of the
PETRA III synchrotron, DESY, Hamburg equipped with a
PILATUS 6M detector and an MD3 diffractometer. The data
were integrated and scaled using XDS (Kabsch, 2010),
yielding a data set to 2.40 Å resolution. The crystal belonged
to the tetragonal space group I41 (No. 80), with unit-cell
parameters a = b = 85.88, c = 107.67 Å. A high Wilson B factor
of 61.1 Å2 was reported by XDS. Solvent-content analysis
based on the Matthews coefficient indicated the presence of
one molecule in the asymmetric unit with 43% solvent
content. The structure was solved by maximum-likelihood
molecular replacement with Phaser (McCoy et al., 2007) as
implemented in the Phenix GUI (Liebschner et al., 2019)
utilizing the human IL-12B chain extracted from PDB entry
5mj3 (Desmet et al., 2014) as a search model. The model was
iteratively built and refined in Coot (Emsley et al., 2010) and
BUSTER (Blanc et al., 2004) or phenix.refine (Adams et al.,
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Table 1
Crystallization conditions for DSCAMIg7–Ig9 for the wild-type and GD-derived proteins.
HEK293T HEK293 GlycoDelete
Protein sample 5 mg ml1 in 20 mM HEPES pH 7.4, 100 mM NaCl,
1 mM DTT
7.5 mg ml1 in 20 mM HEPES pH 7.4, 100 mM NaCl,
1 mM DTT
Initial crystal
Screen The PEGs II Suite The PEGs II Suite
Condition H9: 0.05 M magnesium acetate, 10%(w/v) PEG 8000,
0.1 M sodium acetate
H8: 0.2 M calcium acetate, 10%(w/v) PEG 8000.
0.1 M HEPES pH 7.5
Protein sample 7 mg ml1 in 20 mM HEPES pH 7.4, 100 mM NaCl,
1 mM DTT
7 mg ml1 in 20 mM HEPES pH 7.4, 100 mM NaCl,
1 mM DTT
Optimized condition 0.05 M magnesium acetate, 16%(w/v) PEG 8000 0.2 M calcium acetate, 10%(w/v) PEG 8000,
0.1 M HEPES pH 7.5, 3%(v/v) glycerol
Optimized crystal mounted in a cryo-loop
Diffraction pattern
Diffraction limit (Å) 8 1.85
2010). The refinement strategy and progress was periodically
checked with the PDB-REDO server (Joosten et al., 2014).
Riding H atoms were utilized during refinement for stricter
geometry restraints and individual isotropic atomic displace-
ment parameters were refined per atom. Some loops, in
particular in the C-terminal domain, could not be unambigu-
ously traced. The model was refined to an R factor of 0.229 and
an Rfree of 0.265. The final data-collection and refinement
statistics are summarized in Table 2.
The crystallization and structure determination of the CSF-
1–CSF-1RD1–D3 complex has previously been reported (Felix
et al., 2015). In brief, the data were processed in space group
I41 (unit-cell parameters a = 142.99, b = 142.99, c = 139.32 Å)
and the structure was solved by maximum-likelihood mole-
cular replacement (MR) in Phaser using the crystal structures
of CSF-1 (PDB entry 3uf2; Elegheert et al., 2012) and CSF-
1RD1–D3 as found in the hIL-34–CSF-1RD1–D3 crystal structure
(PDB entry 4dkd; Ma et al., 2012). Initial refinement was
performed in BUSTER (Blanc et al., 2004) using rigid-body
refinement in the first macrocycle. The final refinement steps
were carried out in Phenix after the addition of glycan chains
on Asn73, Asn45, Asn153 and Asn275 to the model. The final
R factors reported by Phenix were R =
0.223 and Rfree = 0.261; the model was
further validated using MolProbity
(Chen et al., 2010).
3. Results
3.1. Purified glycoproteins produced in
GlycoDelete are reduced in size owing
to glycan truncation
To verify the consistent and homo-
geneous truncation of glycans through
the use of the GlycoDelete cell line, we
performed a comparative analysis of
two highly glycosylated cell-surface
receptor fragments and one cytokine.
Expression vectors with identical
protein constructs incorporated were
expressed in HEK293T cells and HEK
GlycoDelete cells under similar condi-
tions. As has been observed with other
engineered HEK cell lines, the protein
yield for the GlycoDelete cell line is
lower (approximately 60% compared
with the wild type after purification).
The glycoproteins produced from
GlycoDelete cells consistently have a
lower molecular weight as identified by
SDS–PAGE (Supplementary Fig. S1).
However, the shift in molecular weight
is minimal for IL-12B and DSCAM,
whereas for CSF-1RD1–D3 it entails a
very substantial reduction of more than
10 kDa. To assess the level of glycosyl-
ation, each sample was treated with PNGase F to identify the
size of the proteins in the absence of glycosylation. IL-12B
appears to contain two major glycan populations when
produced in HEK293T cells, while only a single band is visible
in GD-derived IL-12B. PNGase F treatment leads to an
apparent single population that is approximately 5 kDa
smaller (Supplementary Fig. S1). PNGase F treatment of
DSCAM is efficient both for material produced in HEK293T
and GD cells, leading to a further size reduction of 5 kDa.
There is a small shift in the elution profile of DSCAM from
size-exclusion chromatography, with the GD material eluting
at a slightly longer retention time (Fig. 1a). The shift in
molecular weight as one switches from wild-type to GD
HEK293S cells is most pronounced for CSF-1RD1–D3
(Supplementary Fig. S1 and Fig. 2a). Comparison of the size-
exclusion chromatography profiles of CSF-1RD1–D3 derived
from HEK293T and HEK293 GlycoDelete cells on an analy-
tical Superdex 200 Increase 10/300 GL column showed that
CSF-1RD1–D3 of GD origin elutes 1.5 ml later (with a total bed
volume of 24 ml), indicating a remarkably longer retention
time on the column (Fig. 2a). This decrease in molecular
weight was confirmed by SDS–PAGE gel analysis, where
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Table 2
Crystallographic data-collection and refinement statistics.
Values in parentheses are for the highest resolution shell.
DSCAMIg7–Ig9 IL-12B CSF-1–CSF-1RD1–D3
Wavelength (Å) 0.976 1.033 0.976
Resolution range (Å) 84.81–1.85 (1.89–1.85) 67.41–2.40 (2.49–2.40) 49.71–2.80 (2.97–2.80)
Space group C2 I41 I41
a, b, c (Å) 78.6, 71.4, 92.2 85.88, 85.88, 107.67 143.00, 143.00, 138.32
, ,  () 90, 113.1, 90 90, 90, 90 90, 90, 90
Total reflections 148955 (9215) 123592 (9760) 235463 (37046)
Unique reflections 39662 (2418) 15233 (1486) 34125 (5448)
Multiplicity 3.8 (3.8) 8.11 (6.6) 6.9 (6.8)
Completeness (%) 99.0 (97.4) 99.7 (97.4) 99.8 (99.2)
Mean I/(I) 12.8 (1.6) 12.2 (0.8) 20.7 (2.3)
Wilson B factor (Å2) 43.1 60.25 82.3
Rmerge 0.044 (0.874) 0.117 (1.564) 0.059 (0.864)
Rmeas 0.051 (1.011) 0.125 (1.698) 0.064 (0.815)
Rp.i.m. 0.026 (0.502) 0.044 (0.649) 0.024 (0.351)
CC1/2 1.0 (0.7) 0.998 (0.487) 0.999 (0.74)
Reflections used in refinement 37658 (2753) 15215 (1480) 34116 (3318)
Reflections used for Rfree 2001 (153) 1511 (144) 1706 (165)
Rwork 0.189 (0.289) 0.229 (0.365) 0.223 (0.409)
Rfree 0.217 (0.303) 0.265(0.437) 0.261 (0.465)
No. of non-H atoms
Total 2564 2412 6657
Macromolecules 2281 2306 6370
Ligands 116 73 287
Solvent 167 33 n.a.
No. of protein residues 292 295 833
R.m.s.d., bond lengths (Å) 0.01 0.005 0.006
R.m.s.d., angles () 1.80 1.04 1.094
Ramachandran favored (%) 96.9 95.79 95.6
Ramachandran allowed (%) 3.1 4.21 4.4
Ramachandran outliers (%) 0.0 0.00 0.0
Average B factor (Å2)
Overall 36.9 66.8 100.3
Macromolecules 33.2 66.4 97.4
Ligands 74.8 85.7 164.6
Solvent 60.4 56.0 n.a.
No. of TLS groups 4 n.a. 18
PDB code 6zr7 6sff 4wrl
the GD-derived CSF-1RD1–D3 runs 10 kDa lower than
CSF-1RD1–D3 with wild-type glycans and runs only slightly
higher than fully deglycosylated CSF-1RD1–D3, indicating a
decreased size and increased homogeneity that are entirely
attributed to the change in glycosylation (Fig. 2a). Both the
CSF-1R and DSCAM GlycoDelete materials show lower
molecular-weight bands on the SDS–PAGE. This possibly
indicates that the truncation of the glycans makes the proteins
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Figure 1
Structural analysis of DSCAMIg7–Ig9 derived from HEK293 GD. (a) Comparison of HEK293T and HEK293 GD-derived DSCAMIg7–Ig9; the inset shows
reduced SDS–PAGE analysis of the purified proteins. (b) Cartoon representation showing four copies of DSCAMIg7–Ig9 that form an oligomer by
crystallographic symmetry around the glycan stub. The asymmetric unit contains a single copy. (c) Detailed view of the accommodation of the glycan stub
at residue Asn795 in the Ig7–Ig9 interface. The inset shows a schematic representation of the glycan. (d) An OMIT map of the same glycan stub
contoured at 3. (e) Representative electron density around the glycan at position Asn795. The 2mFo  DFc electron-density map is shown as a gray
mesh (contoured at 1). Residual positive and negative mFo  DFc electron-density maps (contoured at 3) are shown in green and red, respectively.
more sensitive to degradation, because the glycans cover a
smaller area of the protein surface. Clearly, the processing of
N-glycosylation in the GlycoDelete cell line has an effect on
the overall size and homogeneity of the glycoproteins.
3.2. GlycoDelete facilitates crystal structure determination
of the netrin-binding portion of DSCAMIg7–Ig9
Down syndrome cell-adhesion molecule (DSCAM) is a cell-
surface glycoprotein with an extensive ectodomain consisting
of ten immunoglobulin domains and six fibronectin domains.
The DSCAM gene is situated on chromosome 21 and is
overexpressed in Down syndrome patients (Yamakawa et al.,
1998). DSCAM has been implicated in congenital heart
disease (Grossman et al., 2011), and in Drosophila DSCAM is
involved in axon guidance and neuronal wiring (Schmucker et
al., 2000; Meijers et al., 2007). DSCAM interacts with several
guidance molecules, notably netrin (Ly et al., 2008). To further
characterize the portion of the ectodomain of human DSCAM
that interacts with netrin, we produced a truncated fragment
consisting of immunoglobulin domains Ig7, Ig8 and Ig9. There
are five putative N-glycosylation sites in this fragment
according to the NetNGlyc 1.0 server (Blom et al., 2004).
Purified DSCAMIg7–Ig9 protein derived both from wild-type
and GD cells was concentrated to 5–7.5 mg ml1 and was
submitted to crystallization using the same set of crystal-
lization screens. Crystals were obtained from both sources
using similar mother-liquor formulations from related condi-
tions that are present in The PEGs II Suite from Qiagen (see
Table 1). Wild-type-derived rod-shaped crystals were obtained
of significant size and good morphology, but X-ray diffraction
screening on the microfocus beamline P14 only resulted in
diffraction patterns to 8 Å resolution. GD-derived crystals
from the initial condition diffracted to 2.5 Å resolution and
further optimization of the conditions resulted in a complete
data set from a single crystal at 1.85 Å resolution (Table 2).
The crystal structure of human DSCAMIg7–Ig9 contains one
molecule in the asymmetric unit. The residues Val595–Glu884
are visible in the electron density of the refined structure.
One-residue cloning scars were observed at both of the
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Figure 2
Structural analysis of CSF-1RD1–D3 derived from HEK293 GD. (a) Comparison of HEK293T and HEK293 GD-derived CSF-1RD1–D3; the inset shows
reduced SDS–PAGE analysis of the purified proteins. (b) Van der Waals contacts between GD-type glycans on Asn275. (c) Crystal-packing contacts
between symmetry-related glycans. The inset shows a schematic representation of the glycan. (d) The GD-type glycan on Asn73 is -1,6-fucosylated. The
2mFo  DFc electron-density map is shown as a gray mesh. Residual positive and negative mFo  DFc electron-density maps (contoured at 3) are
shown in green and red, respectively.
protein termini (Thr594 and Glu885, respectively). Only the
C-terminal 6His tag was not visible. The fragment corre-
sponds to three immunoglobulin (Ig)-type C2 domains, each
consisting of two layers of antiparallel -sheets held together
by a conserved disulfide bond. Clear electron density for the
glycan chains was observed in all three Ig domains at residues
Asn666, Asn710, Asn748 and Asn795. The predicted glycan at
Asn658 was not observed in the electron density. For three
solvent-exposed glycosylation sites, the glycan stub is only
partially visible in the electron density. Interestingly, the
glycan stub attached to Asn795 within the Ig9 domain shows
the full N-glycosylation pattern (Neu5AcGalGlcNAc) of the
HEK293 GlycoDelete cell line (Figs. 1c, 1d and 1e). This
glycan plays a key role in the assembly of a crystallographic
tetramer formed by the interaction of two Ig9 and two Ig7
domains (Fig. 1b). The glycan stub sits at the center of this
oligomer and makes contacts with the symmetry-related
glycan stub from the other Ig9 molecule that is part of the
interface (Figs. 1b and 1c). The stub occupies a central portion
of the Ig7–Ig9 interface (Figs. 1b, 1c and 1d), making hydrogen
bonds between the glycan units and protein residues from
neighboring DSCAMIg7–Ig9 molecules.
This raises the question whether the truncated glycan stub
may create artificial protein–protein interfaces. The most
critical question that the human DSCAMIg7–Ig9 structure could
answer is whether the dimer interface that has been observed
in the Drosophila DSCAM Ig7 domain is evolutionarily
conserved (Li et al., 2016; Sawaya et al., 2008). An analysis of
the buried surface areas of all of the contacts occurring in the
crystal lattice reveals that the most extensive protein interface
is formed between Ig7 and a symmetry-related Ig7 domain
(830 Å2). When this protein interface is compared with the
Ig7–Ig7 interface observed in available Drosophila DSCAM
crystal structures, it is remarkably similar (Supplementary Fig.
S2). This indicates that the glycan stub-mediated crystal
contacts have not disrupted the functional oligomerization of
the DSCAM Ig7–Ig9 fragment in the crystal lattice. Within the
Ig9–Ig7–Ig7–Ig9 tetramer interface, the protein interfaces
contribute a buried surface area of 1397 Å2 (Ig9–Ig9 = 349 +
Ig9–Ig7 = 218 + Ig7–Ig7 = 830 Å2). The glycan stub extending
from Ig9 that mediates the crystal contacts contributes an
additional 345 Å2, which is more than the Ig9–Ig7 protein
interface alone. We conclude therefore that the rigidity of the
glycan stub substantially contributes to crystal formation, but
without disrupting the biologically relevant dimerization of
the receptor fragment.
3.3. GlycoDelete glycan stubs contribute to the crystal lattice
in CSF-1–CSF-1RD1–D3 crystals
As a member of the class III receptor tyrosine kinases,
colony-stimulating factor 1 receptor (CSF-1R) consists of an
ectodomain comprising five Ig-like domains, a transmembrane
helix and an intracellular kinase domain. Activation occurs
through the binding of CSF-1 or IL-34 to the second (D2) and
third (D3) Ig domains in the CSF-1R ectodomain, eliciting
ligand-induced dimerization and initiation of the intracellular
signaling cascade (Verstraete & Savvides, 2012). CSF-1R
signaling is required for survival, differentiation and prolif-
eration in cells of the mononuclear phagocytic cell lineage
such as macrophages, monocytes and placental trophoblasts
and cells of the central nervous system such as microglia cells
(Stanley & Chitu, 2014).
In order to obtain well diffracting crystals, expression in
glycan-engineered HEK cells was combined with the intro-
duction of point mutations at each of the confirmed N-linked
glycosylation sites (Asn73, Asn153, Asn240 and Asn275),
mutating the N-glycosylated asparagine to glutamine. Only
three of the mutants proved to be amenable for large-scale
production, as initial expression tests showed that abolishing
the Asn73 glycosylation site resulted in loss of expression. In
the first instance, we expressed the glycosylation mutants in
HEK293T and HEK293S MGAT1/ cells. Crystals of the
receptor expressed in HEK293T cells looked like spherulites
and did not diffract, while crystals containing the receptor with
HEK293S MGAT1/ glycans had a rectangular appearance
and diffracted to a high-resolution limit of 4.5 Å; they could be
indexed in space group I41, with unit-cell parameters a = b =
143.0, c = 139.2 Å. In order to further improve the X-ray
diffraction quality of the crystals, we attempted to trim the
glycans of the protein produced in HEK293S MGAT1/ to
the first GlcNAc residue by EndoH digestion. However,
truncation of all of the remaining glycans resulted in a
pronounced reduction in solubility and crystal screens could
only be set up at 4 mg ml1, albeit without yielding crystal-
lization hits. A less drastic truncation of the N-linked glycans
could be achieved by expressing the CSF-1RD1–D3 glycosyla-
tion mutants in the GlycoDelete cell line. Each of the
CSF-1RD1–D3 constructs was transfected in GlycoDelete cells
according to the same protocol for HEK293T and HEK293S
MGAT1/ cells. The final yield of purified CSF-1RD1–D3 was
reduced to about 2 mg per litre of culture, which is still enough
to allow extensive screening of crystallization conditions.
Despite the decrease in glycan size, the CSF-1–CSF-1RD1–D3
complex retained a solubility close to that of the wild-type
material and could be concentrated to 7.4 mg ml1. After
extensive screening, crystals appeared in related conditions
from the Crystal Screen Lite and Index screens. Data collec-
tion on the ID23-1 beamline at the ESRF synchrotron resulted
in a data set with a high-resolution limit of 2.8 Å. These high-
resolution data allowed us to rationalize the impact of the
glycan engineering on crystal lattice formation. Crystals from
HEK293S MGAT1/ cells have a similar packing to those
obtained from GlycoDelete, based on the similarity in space
group and unit-cell parameters. This indicates that protein–
protein interactions dominated the crystal lattice formation,
but the reduction in glycan structure improved the crystal
order, leading to better diffraction properties, as observed for
the DSCAMIg7–Ig9 crystals. The N240Q point mutation was
crucial to allow crystal-packing contacts between symmetry-
related D3 domains (Fig. 2b). The side chain of Gln240 points
towards the D3 packing interface, leaving no space to
accommodate an N-linked glycan. Additionally, the same
interface shows a contribution of the GD-type glycan at
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Asn275 to lattice formation by van der Waals contacts with its
symmetry-related counterparts (Fig. 2b). Such GD glycan-
mediated packing interactions were also observed for domain
1, where the N-acetylneuraminic acid groups of two Asn153-
linked glycans form hydrogen bonds (Fig. 2c, Supplementary
Fig. S3). Finally, density for an -1,6-linked fucose was
observed on the Asn73 glycan, confirming that this is a
possible modification for a GD-type glycan.
3.4. GlycoDelete cells do not alter the structural glycan on
IL-12B but reduce the size and heterogeneity of the other
glycans
IL-12B is a soluble cytokine receptor-like protein associated
with the heterodimeric pro-inflammatory cytokines inter-
leukin-12 (IL-12) and interleukin-23 (IL-23). IL-12B is secreted
as a monomer (denoted IL-12p40) and as a homodimer
(denoted IL-12p80). IL12B can also form a disulfide-linked
interaction mediated by Cys197 on murine IL-12p40 to form
heterodimeric cytokines with the IL-12p35 subunit, resulting
in IL-12, or the IL-23p19 subunit, resulting in IL-23. The
IL-12p40 and IL-12p80 oligomers are competitive inhibitors of
IL-12 and IL-23 signaling as they can bind to the IL-12R1
receptor, which is the low-affinity receptor for these cytokines.
The IL-12p80 homodimer has been attributed with pleiotropic
agonistic effects ranging from modulating the chemotactic
behavior of macrophages and dendritic cells to triggering
lymphotoxin- production in microglia (Cooper & Khader,
2007); however, more research will be necessary for a more
complete functional annotation of this molecular species.
The crystal structure of murine IL-12B presented here
(Fig. 3b) displays high overall structural similarity to human
IL-12B (r.m.s.d. of 0.85 Å over 224 C atoms), which would be
expected from the 66% sequence identity between them. The
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Figure 3
Structural analysis of IL-12B derived from HEK293 GD. (a) Comparison of HEK293T and HEK293 GD-derived IL-12B; the inset shows SDS–PAGE
analysis of the purified proteins under reducing conditions. (b) Cartoon representation of the IL-12B homodimer formed through crystallographic
symmetry (a twofold crystallographic axis is present at Cys197). (c) Close-up of the immature N-linked glycan present on Asn220 and its extensive
interactions with the neighboring protein. The inset shows a schematic representation of the glycan; the mannose residues that could not be readily
identified in the electron density are partially transparent. (d) Representative electron density around the glycan at position Asn220. Density at the top
left belongs to a symmetry mate. The 2mFo  DFc electron-density map is shown as a gray mesh. Residual positive and negative mFo  DFc electron-
density maps (contoured at 3) are shown in green and red, respectively.
IL-12p40 protomer adopts an S-like conformation, with the Ig-
like D1 sitting, out of plane, at a near-perpendicular angle to
D2, followed by D3, in plane, again at a near-perpendicular
angle (Fig. 3b). The fibronectin domains D2 and D3 form what
is known as the cytokine-binding homology region (CHR).
The CHR should contain a WSXWS motif, which is a hallmark
of type 1 cytokine receptors, in the C-terminal domain (D3). A
degenerate form of this motif is present in the segment 323-
Cys-Ser-Lys-Trp-Ala-327. Unlike the canonical motif, this
sequence is not amenable to C-mannosylation and does not
engage in an extensive zipper-like arrangement. The crystallo-
graphic twofold axis present in the I41 lattice is located at
Cys197, thereby forming a crystallographic homodimer. Aside
from the homotypical disulfide, the interface area is very
limited in size (287 Å2) and lacks specific interactions (13
interface residues per protomer and no hydrogen bonds or salt
bridges).
Only the N-linked glycan at Asn220 is clearly present
(Fig. 3c), while other glycosylation sites are likely to be flexible
or less occupied, as suggested by the electrophoretic mobility
of the recombinant protein (Supplementary Fig. S1). Mouse
IL-12B was reported to contain a peculiar N-glycosylation
pattern (Bootz et al., 2016), and this glycan is of the immature
type and not a GlycoDelete trisaccharide (Figs. 3c and 3d).
Extensive van der Waals contacts are present between Trp24
and the nonterminal NAG sugar as well as hydrogen bonds
between Met23, Glu34 and His105 and other parts of the
glycan (Fig. 3c). The electron density allows the modeling of a
Man4GlcNAc2 glycan. Previous research and DNA sequencer-
aided fluorophore-assisted carbohydrate electrophoresis
analysis identified this glycan to be Man9GlcNAc2 or
Man8GlcNAc2 (Fig. 3d). Thus, it appears that the immature
glycan is needed for the proper functioning of IL-12B, prob-
ably to ensure proper folding and stability. Although the GD
cell line was engineered to alter the glycosylation machinery, it
does not affect the formation and retention of the immature
glycan. This immature glycan is probably formed and partially
shielded from the solvent prior to reprocessing by the EndoT
enzyme. The immature glycan is located between the D1 and
D2 domains and may be difficult to access by the EndoT
enzyme. We conclude that it is a critical feature of the GD cell
line that the glycosylation is only reduced after it passes into
the Golgi, as it retains the capability to secrete glycoproteins
that require immature glycans for folding.
4. Discussion
The heterogeneity in N-glycosylation (NG) has been a long-
standing issue in structural biology (Chang et al., 2007) and is
commonly addressed at three different time points during
protein expression and purification. (i) The NG motif (Asn-
Pro-Ser/Thr) is disrupted by mutagenesis during construct
design. (ii) The choice of expression host takes into consid-
eration the capability of the host glycosylation machinery to
produce homogeneous glycans. (iii) After protein expression,
the purified protein can be enzymatically treated with
recombinantly produced endoglycosidases or exoglycosidases
to truncate all of the glycans present into stubs.
To disrupt the NG motif, the asparagine residue is often
mutated to a glutamine, which is no longer a substrate for the
oligosaccharyltransferase. Other less conservative substitu-
tions of the asparagine, or targeting the Ser/Thr site that is part
of the NG motif, will also disrupt the glycosylation of a specific
site. However, not all NG sites can be mutated, as some
glycosylation sites are crucial for proper protein folding and
stability. Careful exploration of mutants is advisable (Felix et
al., 2015; Verstraete et al., 2017, 2014), but can become a
prohibitively daunting undertaking when many NGs are
present on the protein(s) of interest. It is of course possible to
obtain diffraction-quality crystals from glycoproteins and their
complexes with wild-type HEK293 cells (Felix et al., 2016;
Finci et al., 2014; Liu et al., 2018), but for many glycoproteins
crystallization is reported but the structure is never deter-
mined (see, for example, Kulahin et al., 2004). As illustrated by
the case study on DSCAMIg7–Ig9, it is possible to obtain well
proportioned crystals from wild-type HEK cells that unfor-
tunately do not diffract X-rays well. Using the modified GD
cell line led to the production of DSCAMIg7–Ig9 protein that is
essentially identical in composition to the wild-type material,
except for a reduction in the complexity of the five glycans
that are present. The crystallization conditions for wild-type
and GD-derived DSCAMIg7–Ig9 are almost identical (Table 1),
yet a crystal structure could only be determined with the GD-
derived DSCAMIg7–Ig9 crystals.
Alternative strategies that facilitate the production of target
proteins with less complex and enzyme-treatable N-glycosyl-
ation are often followed (Aricescu & Owens, 2013; Büssow,
2015). The choice of expression host strongly affects the size,
complexity and homogeneity of N-glycosylation. Insect cell
lines produce paucimanosidic NG, yeast cell lines produce
high-mannose NG and mammalian cell lines tend to produce a
complex mix of NG (Van Landuyt et al., 2019). Especially for
structural studies on human and other mammalian proteins,
mammalian cell lines can be employed that are engineered to
modify the enzymatic production of N-glycans. A highly
effective enzyme to target in the glycosylation pathway is N-
acetylglucosaminyltransferase I (MGATI/GnTI). Without this
enzyme, the glycosylation pathway stalls at the Man5GlcNac2
stage. These glycans are no longer recognized by certain
lectins such as ricin. The CHO Lec3.2.8.1 (Chaney et al., 1989)
and HEK293S MGAT1/ (Reeves et al., 2002) cell lines lack
N-glycans of high complexity and have been successfully used
in crystallization efforts. While this cell line has yielded many
glycoprotein crystals with good diffraction properties, further
reduction of the glycan complexity could be beneficial for
structural characterization by X-ray crystallography.
In addition to cell-line engineering, the N-glycosylation
pathway can also be manipulated by the addition of
N-glycosylation processing inhibitors during protein expres-
sion. Two well known inhibitors are kifunensine and swain-
sonine, which halt N-glycosylation by inhibiting ER-resident
-mannosidase I and Golgi-resident -mannosidase II,
respectively (Elbein et al., 1982, 1990). These inhibitors lead to
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more homogeneous glycans of the high-mannose type. Kifu-
nensine is more used than swainsonine since it is active at
lower concentrations. Glycoproteins produced in kifunensine-
treated HEK293T cells can be directly amenable to crystal-
lization (Felix et al., 2015), although more often the glycans are
further trimmed by endoglycosidase digests. To further reduce
the size and heterogeneity of NG, enzymatic treatment with
endoglycosidases and exoglycosidases can be applied. Jack-
bean mannosidase can be used to trim high-mannose glycans
to a trisaccharide Man-GlcNAc2 core (Bloch et al., 2018).
More commonly, endoglycosidase H (EndoH) is used, since it
cleaves high-mannose-type NG glycans within the GlcNAc–
GlcNAc core to leave a single GlcNAc unit attached to the
asparagine (Imperiali & O’Connor, 1999). Such high-
mannose-type glycans are for example produced by the
aforementioned HEK293S MGAT1/ cell line, and protein
expression in MGAT1/ cells is often combined with EndoH
treatment. This has the advantage that the preservation of a
single mannose unit maintains the solubility of the glycopro-
tein. However, this two-step procedure can drastically reduce
the protein yield, and may still result in aggregation after
enzymatic treatment. This is nicely illustrated by the case
study presented here on the CSF-1R fragment, which aggre-
gated after EndoH treatment. The GD cell line has the
advantage that the reduction in glycan size and its complexity
occurs within the cell during protein expression, and if the
glycoprotein is secreted in sufficient quantities no further
processing of the glycans is required.
It is important to note that the general glycosylation
machinery is not affected in the GD cell line, despite the
removal of the N-acetylglucosaminyltransferase I and the
redirection of EndoT to the Golgi. This is illustrated by the
case study on IL-12B, which requires an immature glycan for
proper folding. Aside from the more diverse complex and
hybrid-type glycans, immature ER-type or high-mannose-type
glycans are common in the mammalian proteome (Riley et al.,
2019) and on viral spike proteins (Watanabe et al., 2020).
Solvent accessibility to the N-linked glycosylation site in the
context of the folded protein is a key factor determining the
potential maturation of the glycan (Lee et al., 2014). The
immature glycan was clearly present in the crystal structure of
IL-12B based on recombinant protein produced by GD cells,
illustrating the general versatility of this cell line for structural
biology applications.
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